A new partnership between Pfizer, EMD Serono, Friends, and SITC is looking at the overarching goal of identifying opportunities within the evolving field of immunotherapy and prioritize policy changes necessary to address challenges and accelerate progress for patients. By initially convening a small, but representative group of scientific, clinical, patient, policy and industry thought leaders to shape a multi-stakeholder process, this effort will develop an Immuno-Oncology strategic policy plan to accelerate progress across multiple oncology disease states.